Givastomig

Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma[1].

Product Specifications

CAS Number

[2762499-30-7]

Product Name Alternative

TJ-CD4B; ABL111; TJ033721

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

Claudin; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/givastomig.html

Purity

98.556

Molecular Weight

(201.929 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Ku G, et al. A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2025 Jun 30:10.1158/1078-0432.CCR-24-4280. |[2]Gao J, et al. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer. 2023 Jun;11 (6) :e006704.